Mesothelin Inhibitor Market: Competitive Landscape, Pipeline, and Market Analysis 2024

Mesothelin, also known as MSLN, is a protein that is encoded by the MSLN gene in humans. Although it has been proposed that mesothelin may be involved in cell adhesion, its biological function is unknown. Mesothelin is over-expressed in several human tumors, including mesothelioma, ovarian cancer, pancreatic adenocarcinoma, lung adenocarcinoma, and cholangiocarcinoma. Mesothelin binds MUC16 (also known as CA125), indicating that the interaction of mesothelin and MUC16 may contribute to tumor implantation and peritoneal spread by cell adhesion. The mechanism of action (MOA) of Mesothelin Inhibitor is that it works by blocking the binding of mesothelin to its receptors on the cancer cell surface. This interference can prevent the activation of downstream signaling pathways that promote tumor growth and survival, and some antibodies can recruit immune cells, such as natural killer (NK) cells, to recognize and destroy mesothelin-expressing cancer cells. This immune-mediated cytotoxicity can enhance the anti-tumor effects.

Mesothelin Inhibitors has a vital role in the treatment of adenocarcinoma, adnexal diseases, bronchial neoplasms, digestive system diseases, endocrine gland neoplasms, genital diseases, lung neoplasms, and ovarian cancer, among others. The increased prevalence of ovarian cancer and other neoplasm may create a great opportunity for the Mesothelin Inhibitors market. For instance, according to the World Cancer Research Fund International 2020, Ovarian cancer is the 8th most commonly occurring cancer in women and the 18th most common cancer overall, and there were more than 313,000 new cases of ovarian cancer in 2020 worldwide. Moreover, the development of novel molecules by many market players is coming up to overcome challenges in therapy. For instance, AbbVie’s ABBV-428 for the treatment of solid tumors is under the various stages of clinical studies.

Mesothelin Inhibitor Market Key Developments:

In December 2020, Bayer and Atara Biotherapeutics enter strategic collaboration for Mesothelin-targeted CAR T-cell therapies for solid tumors.

Drugs under the Pipeline for Mesothelin Inhibitor:

• CRS-207
• LMB-100
• Amatuximab (MORAB-009)
• SS1(DsFv)-PE38
• SZ011
• Pemlimogene Merolisbac (JNJ-64041757)
• ABBV-428
• HPN536
• NI-1801
• NEO-MASCT
• TC-510
• Anti-Mesothelin CAR NK Cells
• Autologous Redirected RNA Meso-CIR T Cells
• Gavocabtagene Autoleucel (TC-210)
• Inezetamab (AMG 994)
• Thorium (227th) Anetumab Corixetan (BAY 2287411)

Clinical Activity and Developments of Mesothelin Inhibitor:

Till July 2023, more than 15 companies have approximately 18 molecules targetting many cancers. For these molecules, more than 12 clinical trials are being conducted and the majority are in phase-2, phase-3 clinical trials by the players across the globe. For instance,

• In April 2019, Eisai completed phase 2, an Open-Label Clinical Trial of MORAb-009 in combination with Pemetrexed and Cisplatin in subjects with mesothelioma sponsored by Morphotek.